GSK plc (BVMF:G1SK34)

Market Cap	518.51B
Revenue (ttm)	230.43B
Net Income (ttm)	39.36B
Shares Out	n/a
EPS (ttm)	9.52
PE Ratio	13.17
Forward PE	10.16
Dividend	1.78 (3.50%)
Ex-Dividend Date	Nov 13, 2025

Volume	1
Average Volume	69
Open	50.95
Previous Close	n/a
Day's Range	50.95 - 50.95
52-Week Range	38.60 - 51.64
Beta	0.23
RSI	65.84
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: G1SK34

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP